Neuropathic Pain Market Forecast02 Jun 2011 • by Natalie Aster
In 2010, two significant events impacted the neuropathic pain market: the launch of Qutenza (8% capsaicin patch; NeurogesX/Astellas) in the US and EU, which represents the first therapy to enter the market in over 2 years; and the highprofile failure of ralfinamide (NW-1029; Newron) for the treatment of neuropathic low back pain.
The report “Neuropathic Pain Market Forecast” by Datamonitor provides an in depth analysis of historic (2005–09) and future (2010–19) seven major market prescription sales dynamics. It includes neuropathic pain and country-specific sales forecasts for key brands, generics and pipeline drugs in the seven major markets to 2019.
- The neuropathic pain market is expected to achieve peak sales of $4.1bn over the forecast period (2010–19) across the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK).
- The pipeline features reformulations as well as drugs displaying novel mechanisms of action in an attempt to satisfy key unmet needs.
- In addition to existing brands expanding into new regions, Datamonitor forecasts a total of eight pipeline candidates to launch during the forecast period 2010–19 across the seven major markets.
- The broad label approval of Nucynta ER (extended-release tapentadol; Johnson & Johnson/Gruenenthal) will drive market growth, while the launch of novel and topical agents will broaden treatment options.
Neuropathic Pain Market Forecast
Published: January 2011
Price: US$ 15,200.00
Report Sample Abstract
HIV-related neuropathic pain affects an estimated 332,000 people in the seven major markets
HIV-NP is one of the most common neurological complications of HIV infection. The prevalence of HIV-NP is increasing, which may be partly attributable to the increased lifespan of HIV-infected patients. This view was supported by a key opinion leader.
“Neuropathic pain is very common in HIV neuropathies, and HIV neuropathies are increasing as HIV sufferers are surviving longer.” (EU key opinion leader)
Approximately 57% of HIV-infected/AIDS patients express clinical evidence of peripheral neuropathy (Ellis et al., 2010). Prevalence rates of neuropathic pain associated with HIV vary across the seven major markets, with values reported to be as low as 21% (Ellis et al., 2010) and as high as 62% (Larue et al., 1997). However, it is worth noting that in the study conducted by Larue et al. in 1997, which obtained some of the highest prevalence, values were reported for HIV-infected inpatients. In the same study, 30% of HIV-infected outpatients were reported to suffer from HIV-NP, prevalence more in line with the other epidemiology studies for this indication.
In applying the prevalence of neuropathic pain reported in HIV patients, Datamonitor estimates the population of patients currently suffering with HIV-NP within each of the seven major markets (see Table 7). It is estimated that around 332,000 patients in the US alone suffer from HIV-NP. However, with the continuing advances in HIV treatment, Datamonitor expects the prevalence of HIV-NP to decline over time.
To order the report or ask for sample pages contact firstname.lastname@example.org